Jubilant Ingrevia has announced a plan to spend ₹500-600 crore annually on capacity expansion, alongside potential acquisitions worth over $500 million. The company aims for 20-25% annual growth by FY27, targeting higher-value products in the nutrition and specialty chemical sectors.
Detailed Coverage
Jubilant Ingrevia is setting a clear growth path by committing to an annual capital spending program of ₹500-600 crore. This investment follows a three-year period where the company already spent ₹2,000 crore to upgrade its manufacturing facilities. The new funds are earmarked for expanding the production of essential ingredients like Vitamin B3, also known as niacinamide, and Vitamin B4, or choline chloride, which are widely used in the food and animal feed industries.
Strategic Expansion and Acquisition Goals
Beyond internal growth, the company is evaluating acquisitions exceeding $500 million. These potential deals are intended to strengthen its footprint in niche markets such as personal care, specialized nutrition, and semiconductor chemicals. By diversifying into these areas, the company aims to move toward higher-value products, which often carry better profit margins than basic chemical intermediates. The company’s management indicated that these moves are part of a broader plan to achieve 20-25 percent annual growth in both revenue and operating profit by fiscal year 2027.
Financial Performance and Market Position
Recent financial results show a positive trend. For the first quarter of FY27, the company reported revenue of ₹1,300 crore, marking a 25 percent increase compared to the same period last year. Operating profit rose by 36 percent to ₹209 crore, and net profit grew by 41 percent to ₹106 crore. As of its recent reporting, the company maintains a healthy balance sheet with a net debt-to-operating profit ratio below 1x, which provides the financial flexibility to fund its expansion plans.
Jubilant Ingrevia holds a significant position in the domestic market, particularly with a 50-55 percent share in choline chloride. The company also positions itself as a key non-Chinese supplier of pyridine and picolines, which are essential building blocks for various industrial applications. This positioning is particularly relevant for global clients looking to reduce supply chain risks associated with heavy reliance on Chinese chemical imports.
Monitorable Factors for Investors
While the expansion plans are ambitious, investors may track the execution of these projects and the timing of any potential acquisitions. Key items to watch include the capacity utilization of the new Bharuch niacinamide plant, which is expected to cross 70 percent by the end of the year, and the progress of the multi-purpose plant at Gajraula. Additionally, as the company enters more specialized fields like semiconductor chemicals, the ability to maintain current profit margins while scaling up will be an important factor in its long-term performance.